ClinicalTrials.gg
Not yet recruitingNCT07277218Updated Nov 2, 2026

Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis

An observational study in Femoropopliteal In-Stent Restenosis (ISR), sponsored by Chunshui He. Not yet recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Chunshui He · Observational

How we know

Updated Nov 2, 2026First site in ChinaPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
6th of 27
600 · median 254
Started
2027
the only one that year
Observational
27 of 80
14 open now
Primary completion
2030-12
later than 33 of 33 live
Registered
73rd of 80
by date

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 6th largest by planned enrollment of the 27 observational ones that give a count, is the only one that started in 2027, is one of 27 observational ones, reaches primary completion later than 33 of the 33 other live ones, and was the 73rd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment. Drug-coated balloons (DCBs) avoid an additional permanent metallic layer, whereas drug-eluting stents provide mechanical scaffolding with local antiproliferative drug delivery. Direct prospective comparative-effectiveness evidence in symptomatic femoropopliteal ISR remains limited.

DEFIER is a prospective, multicenter observational comparative-effectiveness cohort study enrolling up to 600 adults with symptomatic Rutherford category 2-5 femoropopliteal ISR. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. After guidewire crossing and lesion preparation, patients for whom both strategies remain clinically feasible enter the primary comparative cohort. The DCB-first strategy uses IN.PACT Admiral or AcoArt Orchid 0.035, with protocol-defined focal bare-metal bailout stenting permitted when clinically required. The Eluvia-first strategy uses the Eluvia drug-eluting vascular stent.

Participants will be followed for 24 months. The primary outcome is the cumulative incidence of first clinically driven target lesion revascularization (CD-TLR) through 24 months. Comparative analyses will use a prespecified target-trial framework and propensity-score overlap weighting, with death and major target-limb amputation treated as competing events.

03

Conditions studied

  • Femoropopliteal In-Stent Restenosis (ISR)

Keywords

  • in-stent restenosis ; femoropopliteal artery; drug-coated balloon ; drug-eluting stent; peripheral arterial disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with symptomatic Rutherford category 2-5 femoropopliteal in-stent restenosis undergoing clinically indicated endovascular treatment at participating tertiary vascular centers in China. Potentially eligible patients will be screened consecutively. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. The primary comparative cohort includes patients for whom both DCB-first and Eluvia-first strategies remain clinically feasible after lesion preparation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age >18 years. Willing and able to provide written . Rutherford Clinical Category 2-5. Angiographically confirmed ≥50% stenosis or occlusion within a previously implanted superficial femoral or proximal popliteal artery stent more than 30 days after implantation.

The target lesion is within the previously stented segment or extends no more than 3 cm proximally or distally beyond the prior stent.

Total target lesion length ≤30 cm. At least one patent below-the-knee runoff vessel. Willing and able to complete follow-up through 24 months. After lesion preparation, both the DCB-first and Eluvia-first strategies remain clinically feasible.

Exclusion criteria

Exclusion Criteria:

Pregnancy or lactation. Rutherford Clinical Category 0 or 6. Target lesion stenosis \<50%. Target lesion length >30 cm. Severe calcification precluding endovascular treatment. Acute limb ischemia or acute thrombosis of the target limb. Untreated hemodynamically significant aorto-iliac inflow disease. Cerebrovascular accident within 60 days before the index procedure. to required antiplatelet or anticoagulant therapy. Inability or unwillingness to provide . \<2 years or another factor making completion of follow-up unlikely.

Persistent post-preparation anatomy that mandates one treatment strategy and therefore eliminates clinical equipoise.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • DCB-First Strategy Cohort

    Participants whose treating physician selects a drug-coated balloon-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The prespecified DCB platforms are IN.PACT Admiral and AcoArt Orchid 0.035. Protocol-defined focal bare-metal bailout stenting is permitted when clinically necessary. Treatment is not assigned by the research protocol.

    Device: Drug-Coated Balloon-First Strategy

  • Eluvia-First Strategy Cohort

    Participants whose treating physician selects an Eluvia-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The strategy uses the Eluvia Drug-Eluting Vascular Stent System. Treatment is not assigned by the research protocol.

    Device: Eluvia Drug-Eluting Stent-First Strategy

Interventions

  • DeviceDrug-Coated Balloon-First Strategy

    Physician-selected routine-care treatment with either IN.PACT Admiral or AcoArt Orchid 0.035 after lesion preparation. Device size and length are selected according to vessel anatomy and locally approved instructions for use. Protocol-defined focal bare-metal bailout stenting is permitted when clinically required for a suboptimal DCB result.

  • DeviceEluvia Drug-Eluting Stent-First Strategy

    Physician-selected routine-care treatment with the Eluvia Drug-Eluting Vascular Stent System after lesion preparation. Stent diameter and length are selected according to vessel anatomy and locally approved instructions for use.

06

What researchers measure

Primary outcomes

  1. Clinically-Driven Target Lesion Revascularization (CD-TLR)

    Clinically driven target lesion revascularization (CD-TLR) is defined as repeat percutaneous or surgical revascularization of the target lesion, defined as the treated segment plus 5 mm proximally and distally, for ≥50% restenosis or occlusion accompanied by recurrent or worsening limb symptoms, Rutherford-category deterioration, ABI/TBI decline consistent with hemodynamic worsening, including an ABI decline ≥0.15 from the post-procedure reference when applicable, or failure or worsening of tissue loss in patients with chronic limb-threatening ischemia. Events will be independently adjudicated.

    Time frame: 24 months post-procedure

Secondary outcomes

  1. First Clinically Driven Target Lesion Revascularization Through 12 Months

    Number and percentage of participants experiencing first clinically driven target lesion revascularization within 12 months after time zero, using the same prespecified clinical and anatomical definition and independent adjudication procedures as the 24-month primary outcome.

    Time frame: From post-preparation time zero through 12 months

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.

Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 47 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jan 2029 → Dec 2030 and completion Jan 2029 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 11, 2025
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2030was Jan 2029
CompletionEst.
Dec 31, 2030was Jan 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first site in China
Show 10 added (10 China)
  • Xuanwu Hospital, Capital Medical University · Beijing, China
  • Xiamen Cardiovascular Hospital of Xiamen University · Xiamen, China
  • Hangzhou First People's Hospital · Hangzhou, China
  • Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • The Second Affiliated Hospital of Soochow University · Suzhou, China
  • Qingdao Haici Hospital Affiliated to Qingdao University · Qingdao, China
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Zhongshan Hospital, Fudan University · Shanghai, China
  • Hospital of Chengdu University of Traditional Chinese Medicine · Chengdu, China
  • Huashan Hospital, Fudan University · Shanghai, China
Nov 2, 2026
Primary completion
Jan 1, 2029→Dec 31, 2030
Nov 2, 2026
Study completion
Jan 1, 2029→Dec 31, 2030
Nov 2, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedFirst Clinically Driven Target Lesion Revascularization Through 12 MonthsTime frame: From post-preparation time zero through 12 months
Nov 2, 2026
Contact
Study contact's phone or email changed: none listed→•••5601. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    10 sites added — first site in China
    Show 10 added (10 China)
    • Xuanwu Hospital, Capital Medical University · Beijing, China
    • Xiamen Cardiovascular Hospital of Xiamen University · Xiamen, China
    • Hangzhou First People's Hospital · Hangzhou, China
    • Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • The Second Affiliated Hospital of Soochow University · Suzhou, China
    • Qingdao Haici Hospital Affiliated to Qingdao University · Qingdao, China
    • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Zhongshan Hospital, Fudan University · Shanghai, China
    • Hospital of Chengdu University of Traditional Chinese Medicine · Chengdu, China
    • Huashan Hospital, Fudan University · Shanghai, China
    Primary completion Jan 1, 2029→Dec 31, 2030
    Study completion Jan 1, 2029→Dec 31, 2030
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedFirst Clinically Driven Target Lesion Revascularization Through 12 MonthsTime frame: From post-preparation time zero through 12 months
    Contact Study contact's phone or email changed: none listed→•••5601. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07277218
Lead sponsor
Chunshui He
Collaborators
First Affiliated Hospital of Zhejiang University, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology, Department of Vascular Surgery, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, China., Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China., Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China., Department of Vascular Surgery, Huashan Hospital, Fudan University, Shanghai, China., Department of Cardiovascular Surgery, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China., Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China., Biomedical Informatics and Statistics Center, School of Public Health.Fudan University, Shanghai, China., Department of Vascular Surgery, Xuanwu Hospital Capital MedicalUniversity, Beijing, China., Department of Vascular Surgery, School of Medicine, AffiliatedHangzhou First People's Hospital, Zhejiang University, Hangzhou, China.
Responsible party
Chunshui He (Chief physician, Chengdu University of Traditional Chinese Medicine) — Sponsor-investigator
First posted
Dec 11, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

chunshui he, MD
Contact
chunshui_he@163.com
+86 18981885601

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion